Literature DB >> 6836187

Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases.

E Weitzenblum, M Ehrhart, J Rasaholinjanahary, C Hirth.   

Abstract

65 patients with interstitial lung diseases were subdivided into two groups: idiopathic pulmonary fibrosis (IPF) and other interstitial pulmonary diseases (OIP) according to histopathological, immunological and follow-up findings. Arterial blood gases and pulmonary hemodynamics at rest and during steady-state exercise were compared in these two groups (IPF = 31 patients, OIP = 34 patients). The resting PaO2 was significantly lower in the IPF group (p less than 0.001) and regularly worsened during exercise in this group (from 69.6 +/- 11.6 to 56.0 +/- 9.4 mm Hg, p less than 0.001) whereas it did not vary significantly in the OIP group (from 79.2 +/- 13.1 to 75.3 +/- 14.1 mm Hg, NS). Pulmonary artery mean pressure (PPA) was higher in the IPF group (p less than 0.001) as were all indices of pulmonary vascular resistance (PVR). During exercise, PPA markedly increased in the IPF group (from 21.7 +/- 7.8 to 45.3 +/- 16.2 mm Hg) but modestly in the OIP group (from 15.5 +/- 3.7 to 28.3 +/- 9.8 mm Hg). The best relationships were found between PPA, PVR and PaO2, which suggests that pulmonary arterial hypertension in these diseases is not only due to anatomical factors but also to alveolar and arterial hypoxia. Arterial blood gases and pulmonary hemodynamics at rest and during exercise may be of interest for the discrimination of 'true' interstitial fibrosis (IPF) from other interstitial lung diseases (OIP).

Entities:  

Mesh:

Year:  1983        PMID: 6836187     DOI: 10.1159/000194537

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  20 in total

1.  Remodeling of mechanical junctions and of microtubule-associated proteins accompany cardiac connexin43 lateralization.

Authors:  Halina S Chkourko; Guadalupe Guerrero-Serna; Xianming Lin; Nedal Darwish; Joshua R Pohlmann; Keith E Cook; Jeffrey R Martens; Eli Rothenberg; Hassan Musa; Mario Delmar
Journal:  Heart Rhythm       Date:  2012-03-07       Impact factor: 6.343

2.  Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities.

Authors:  Rajeev Saggar; Dinesh Khanna; Daniel E Furst; Shelley Shapiro; Paul Maranian; John A Belperio; Neeraj Chauhan; Philip Clements; Alan Gorn; S Sam Weigt; David Ross; Joseph P Lynch; Rajan Saggar
Journal:  Arthritis Rheum       Date:  2010-12

Review 3.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

4.  Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  David A Zisman; David J Ross; John A Belperio; Rajan Saggar; Joseph P Lynch; Abbas Ardehali; Arun S Karlamangla
Journal:  Respir Med       Date:  2007-07-02       Impact factor: 3.415

5.  Evaluation of hemodynamic changes by use of phase-contrast MRI for patients with interstitial pneumonia, with special focus on blood flow reduction after breath-holding and bronchopulmonary shunt flow.

Authors:  Nanae Tsuchiya; Yuichiro Ayukawa; Sadayuki Murayama
Journal:  Jpn J Radiol       Date:  2012-12-20       Impact factor: 2.374

Review 6.  Management of Pulmonary Hypertension in Patients with Chronic Lung Disease.

Authors:  Joan Albert Barberà; Isabel Blanco
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

7.  High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis.

Authors:  David A Zisman; Arun S Karlamangla; David J Ross; Michael P Keane; John A Belperio; Rajan Saggar; Joseph P Lynch; Abbas Ardehali; Jonathan Goldin
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

8.  VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats.

Authors:  Laszlo Farkas; Daniela Farkas; Kjetil Ask; Antje Möller; Jack Gauldie; Peter Margetts; Mark Inman; Martin Kolb
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

9.  Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.

Authors:  MeiLan K Han; David S Bach; Peter G Hagan; Eric Yow; Kevin R Flaherty; Galen B Toews; Kevin J Anstrom; Fernando J Martinez
Journal:  Chest       Date:  2013-06       Impact factor: 9.410

10.  Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis.

Authors:  David A Zisman; Arun S Karlamangla; Steven M Kawut; Oksana A Shlobin; Rajeev Saggar; David J Ross; Marvin I Schwarz; John A Belperio; Abbas Ardehali; Joseph P Lynch; Steven D Nathan
Journal:  Chest       Date:  2008-01-15       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.